We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App





Germ-Zapping Robot Deactivates SARS-CoV-2 on Surfaces in Two Minutes

By HospiMedica International staff writers
Posted on 12 Oct 2020
A new disinfection robot that destroys hard-to-kill viruses, bacteria and superbugs in hard-to-clean places has been proven to deactivate SARS-CoV-2, the virus that causes COVID-19, on surfaces in two minutes.

The LightStrike Germ-Zapping robot has been developed by Xenex (San Antonio, TX, USA), a provider of UV technology-based disinfection strategies and solutions. More...


Recognizing that superbugs are becoming increasingly resistant to cleaning chemicals, antibiotics and even some hand sanitizers, hospitals are turning to new technology to enhance their existing infection control practices in order to reduce the risk of healthcare-associated infections (HAIs) in their facilities. These infections are caused by microorganisms such as Clostridium difficile (C.diff), methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococci (VRE) that often lurk on high-touch surfaces in healthcare facilities.

Xenex’s LightStrike Germ-Zapping robots use pulsed xenon, an environmentally-friendly inert gas, to create intense bursts of ultraviolet (UV) light that quickly destroys bacteria, viruses, and spores on hospital surfaces without damaging expensive materials. Xenex’s pulsed, high energy, broad spectrum UV light technology is uniquely lethal to microorganisms – its 4300x more intense in peak power than a mercury lamp. Disinfection cycles are fast, allowing disinfection of a patient room in as little as 10 minutes and a surgical suite in 20 minutes or less. Sensors immediately stop the device when motion is detected and the disinfection robot also offers cloud-based reporting of key metrics. More than 40 peer-reviewed studies have been published validating the efficacy of the LightStrike technology. The findings indicate two minutes of pulsed Xenon UV decrease operating room surface contamination by 72.5%.

Related Links:
Xenex


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mammo DR Retrofit Solution
DR Retrofit Mammography
VTE Prevention System
Flowtron ACS900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.